403
Sorry!!
Error! We're sorry, but the page you were looking for doesn't exist.
MRSA therapeutics market to reach $1.8 billion across 7MM in 2034, forecasts GlobalData
(MENAFN- Cision) The methicillin-resistant Staphylococcus aureus (MRSA) therapeutics market across the seven major pharmaceutical markets (7MM*) is forecast to grow at a compound annual growth rate (CAGR) of 3.4%, from $1.3 billion in 2024 to $1.8 billion in 2034, according to GlobalData, a leading intelligence and productivity platform.
GlobalData’s report“ “Methicillin-Resistant Staphylococcus aureus Therapeutics: Seven-Market Drug Forecast”, reveals that market growth will primarily be driven by the anticipated increase in hospitalized incident cases of MRSA, as well as the introduction of five late-stage pipeline products.
Stephanie Kurdach, Infectious Disease Analyst at GlobalData, comments: “Hospitalized incident cases of MRSA in the 7MM are projected to increase at an annual growth rate of 1.10% between 2024 and 2034, reaching over 800,000 hospitalized incident cases by 2034. This is expected to be the biggest driver of growth in the MRSA therapeutics market over the forecast”period.”
Five pipeline products are currently in late-stage development and are expected to launch by 2034. These include Armata Pharm’ceuticals’ bacteriophage, AP-SA02; MicuRx Pha’maceuticals’ 23S ribosomal RNA inhibitor, contezolid/contezolid acefosamil; Citius P’armaceuticals’ antibiotic catheter lock solution, Mino-Lok; GangaGen’Biotechnologies’ topical peptidoglycan inhibitor, P128; and T’nNor Therapeutics’ multitargeting antibiotic, rifaquizinone.
Kurdach continues: “All of the pipeline products in late-stage development offer novel therapy options for patients with MRSA infections. AP-SA02 has the potential to be a first-in-class treatment for MRSA bacteremia. Likewise, Mino-Lok has the potential to be a first-in-class antibiotic catheter lock solution intended to salvage infected central venous catheters. Unfortunately, these therapeutics are only projected to experience moderate uptake due to commercial barriers such as high pricing and limited advantages over the cur”ent standard of care.”
GlobalData forecasts that sales of the pipeline anti-infectives are expected to grow to $106.5 million by 2034. In 2034, sales of the pipeline anti-infectives will contribute 6% of total sales in the 7MM.
Despite the anticipated launch of several innovative therapeutics, generic erosion will represent a barrier to growth over the forecast period. Zinforo (ceftaroline), Mabelio/Zevtera (ceftobiprole), Dalvance/Xydalba (dalbavancin), Baxdela/Quofenix (delafloxacin), Sivextro (tedizolid), and Tygacil (tigecycline) will lose patent protection in major markets during the forecast period, and generic erosion will curtail market growth.
GlobalData’s report“ “Methicillin-Resistant Staphylococcus aureus Therapeutics: Seven-Market Drug Forecast”, reveals that market growth will primarily be driven by the anticipated increase in hospitalized incident cases of MRSA, as well as the introduction of five late-stage pipeline products.
Stephanie Kurdach, Infectious Disease Analyst at GlobalData, comments: “Hospitalized incident cases of MRSA in the 7MM are projected to increase at an annual growth rate of 1.10% between 2024 and 2034, reaching over 800,000 hospitalized incident cases by 2034. This is expected to be the biggest driver of growth in the MRSA therapeutics market over the forecast”period.”
Five pipeline products are currently in late-stage development and are expected to launch by 2034. These include Armata Pharm’ceuticals’ bacteriophage, AP-SA02; MicuRx Pha’maceuticals’ 23S ribosomal RNA inhibitor, contezolid/contezolid acefosamil; Citius P’armaceuticals’ antibiotic catheter lock solution, Mino-Lok; GangaGen’Biotechnologies’ topical peptidoglycan inhibitor, P128; and T’nNor Therapeutics’ multitargeting antibiotic, rifaquizinone.
Kurdach continues: “All of the pipeline products in late-stage development offer novel therapy options for patients with MRSA infections. AP-SA02 has the potential to be a first-in-class treatment for MRSA bacteremia. Likewise, Mino-Lok has the potential to be a first-in-class antibiotic catheter lock solution intended to salvage infected central venous catheters. Unfortunately, these therapeutics are only projected to experience moderate uptake due to commercial barriers such as high pricing and limited advantages over the cur”ent standard of care.”
GlobalData forecasts that sales of the pipeline anti-infectives are expected to grow to $106.5 million by 2034. In 2034, sales of the pipeline anti-infectives will contribute 6% of total sales in the 7MM.
Despite the anticipated launch of several innovative therapeutics, generic erosion will represent a barrier to growth over the forecast period. Zinforo (ceftaroline), Mabelio/Zevtera (ceftobiprole), Dalvance/Xydalba (dalbavancin), Baxdela/Quofenix (delafloxacin), Sivextro (tedizolid), and Tygacil (tigecycline) will lose patent protection in major markets during the forecast period, and generic erosion will curtail market growth.
Legal Disclaimer:
MENAFN provides the
information “as is” without warranty of any kind. We do not accept any
responsibility or liability for the accuracy, content, images, videos,
licenses, completeness, legality, or reliability of the information
contained in this article. If you have any complaints or copyright issues
related to this article, kindly contact the provider above.
Comments
No comment